
NGNE Valuation
Neurogene Inc
- Overview
- Forecast
- Valuation
- Earnings
NGNE Relative Valuation
NGNE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NGNE is overvalued; if below, it's undervalued.
Historical Valuation
Neurogene Inc (NGNE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.50. The fair price of Neurogene Inc (NGNE) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price:21.87
Fair
-4.20
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Neurogene Inc. (NGNE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-0.24
EV/EBIT
Neurogene Inc. (NGNE) has a current EV/EBIT of -0.24. The 5-year average EV/EBIT is -3.23. The thresholds are as follows: Strongly Undervalued below -8.46, Undervalued between -8.46 and -5.85, Fairly Valued between -0.61 and -5.85, Overvalued between -0.61 and 2.01, and Strongly Overvalued above 2.01. The current Forward EV/EBIT of -0.24 falls within the Overvalued range.
0.00
PS
Neurogene Inc. (NGNE) has a current PS of 0.00. The 5-year average PS is 145.70. The thresholds are as follows: Strongly Undervalued below -553.98, Undervalued between -553.98 and -204.14, Fairly Valued between 495.54 and -204.14, Overvalued between 495.54 and 845.39, and Strongly Overvalued above 845.39. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-3.21
P/OCF
Neurogene Inc. (NGNE) has a current P/OCF of -3.21. The 5-year average P/OCF is -5.30. The thresholds are as follows: Strongly Undervalued below -9.94, Undervalued between -9.94 and -7.62, Fairly Valued between -2.97 and -7.62, Overvalued between -2.97 and -0.65, and Strongly Overvalued above -0.65. The current Forward P/OCF of -3.21 falls within the Historic Trend Line -Fairly Valued range.
-3.01
P/FCF
Neurogene Inc. (NGNE) has a current P/FCF of -3.01. The 5-year average P/FCF is -4.69. The thresholds are as follows: Strongly Undervalued below -8.66, Undervalued between -8.66 and -6.67, Fairly Valued between -2.70 and -6.67, Overvalued between -2.70 and -0.72, and Strongly Overvalued above -0.72. The current Forward P/FCF of -3.01 falls within the Historic Trend Line -Fairly Valued range.
Neurogene Inc (NGNE) has a current Price-to-Book (P/B) ratio of 1.07. Compared to its 3-year average P/B ratio of 2.20 , the current P/B ratio is approximately -51.13% higher. Relative to its 5-year average P/B ratio of 2.20, the current P/B ratio is about -51.13% higher. Neurogene Inc (NGNE) has a Forward Free Cash Flow (FCF) yield of approximately -23.04%. Compared to its 3-year average FCF yield of -19.63%, the current FCF yield is approximately 17.40% lower. Relative to its 5-year average FCF yield of -19.63% , the current FCF yield is about 17.40% lower.
1.07
P/B
Median3y
2.20
Median5y
2.20
-23.04
FCF Yield
Median3y
-19.63
Median5y
-19.63
Competitors Valuation Multiple
The average P/S ratio for NGNE's competitors is 16035.55, providing a benchmark for relative valuation. Neurogene Inc Corp (NGNE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NGNE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NGNE in the past 1 year is driven by Unknown.
People Also Watch

ALTG
Alta Equipment Group Inc
7.980
USD
0.00%

PINE
Alpine Income Property Trust Inc
14.090
USD
0.00%

GENC
Gencor Industries Inc
14.685
USD
-2.10%

ZYXI
Zynex Inc
2.370
USD
-4.82%

NAUT
Nautilus Biotechnology Inc
0.760
USD
0.00%

CPSS
Consumer Portfolio Services Inc
8.350
USD
+0.60%

DMAC
DiaMedica Therapeutics Inc
4.450
USD
0.00%

ATAI
ATAI Life Sciences NV
3.900
USD
+12.39%

EVI
EVI Industries Inc
21.240
USD
+0.81%

AVNW
Aviat Networks Inc
21.960
USD
0.00%
FAQ

Is Neurogene Inc (NGNE) currently overvalued or undervalued?
Neurogene Inc (NGNE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.50. The fair price of Neurogene Inc (NGNE) is between NaN to NaN according to relative valuation methord.

What is Neurogene Inc (NGNE) fair value?

How does NGNE's valuation metrics compare to the industry average?

What is the current P/B ratio for Neurogene Inc (NGNE) as of Jul 31 2025?

What is the current FCF Yield for Neurogene Inc (NGNE) as of Jul 31 2025?

What is the current Forward P/E ratio for Neurogene Inc (NGNE) as of Jul 31 2025?
